NAS:ANIP (USA) Also trade in: Germany

ANI Pharmaceuticals Inc

$ 68.47 0.04 (0.06%)
Volume: 97,384 Avg Vol (1m): 113,637
Market Cap $: 824.91 Mil Enterprise Value $: 970.57 Mil
P/E (TTM): 59.54 P/B: 4.05
Earnings Power Value -49.41
Net Current Asset Value -7.01
Tangible Book -0.76
Projected FCF -23.04
Median P/S Value 146.81
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.21
Cash-To-Debt ranked lower than
92.21% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ANIP: 0.21
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 10000, Max: 10000
Current: 0.21
0
10000
Equity-to-Asset 0.46
Equity-to-Asset ranked lower than
75.36% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ANIP: 0.46
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.27, Med: 0.72, Max: 0.96
Current: 0.46
0.27
0.96
Debt-to-Equity 0.92
Debt-to-Equity ranked lower than
85.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ANIP: 0.92
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.1, Med: 0.74, Max: 1.71
Current: 0.92
0.1
1.71
Debt-to-EBITDA 2.47
Debt-to-EBITDA ranked lower than
69.39% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ANIP: 2.47
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.44, Med: 2.85, Max: 14.31
Current: 2.47
-0.44
14.31
Interest Coverage 2.29
Interest Coverage ranked lower than
95.20% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ANIP: 2.29
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.92, Med: 2.42, Max: 25.42
Current: 2.29
1.92
25.42
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.84
DISTRESS
GREY
SAFE
Beneish M-Score -2.90
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.37%
WACC 11.97%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 15.97
Operating Margin ranked higher than
86.62% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ANIP: 15.97
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -11707.36, Med: 9.76, Max: 42.84
Current: 15.97
-11707.36
42.84
Net Margin % 6.58
Net Margin ranked higher than
71.72% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ANIP: 6.58
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -11864.14, Med: 0.2, Max: 51.36
Current: 6.58
-11864.14
51.36
ROE % 7.08
ROE ranked higher than
77.25% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ANIP: 7.08
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -320.53, Med: -10.26, Max: 31.63
Current: 7.08
-320.53
31.63
ROA % 3.19
ROA ranked higher than
78.78% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ANIP: 3.19
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -175.65, Med: 0.37, Max: 18.91
Current: 3.19
-175.65
18.91
ROC (Joel Greenblatt) % 34.43
ROC (Joel Greenblatt) ranked higher than
91.60% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ANIP: 34.43
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -6803.87, Med: 21.18, Max: 127.85
Current: 34.43
-6803.87
127.85
3-Year Total Revenue Growth Rate 38.20
3-Year Revenue Growth Rate ranked higher than
87.56% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ANIP: 37.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 31.05, Max: 385
Current: 37.4
0
385
3-Year Total EBITDA Growth Rate 20.00
3-Year EBITDA Growth Rate ranked higher than
82.17% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ANIP: 19.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -5, Max: 265.9
Current: 19.3
0
265.9
3-Year EPS w/o NRI Growth Rate -0.50
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ANIP: -0.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -13.95, Max: 66.4
Current: -0.5
0
66.4

» ANIP's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ANIP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare SZSE:002022 SHSE:603590 NAS:NITE NAS:CERS NAS:MGNX TSX:ADVZ XPAR:ALCLS SHSE:603896 NAS:FIXX NAS:KNSA NAS:BCRX NYSE:CO TSE:4593 SAU:2070 NAS:NSTG XPAR:STAGR ROCO:4174 NAS:VYGR NAS:VNDA NAS:CBAY
Traded in other countries BSFA.Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a specialty pharmaceutical company. The Company, together with its subsidiary is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Ratios

Current vs industry vs history
PE Ratio (TTM) 59.54
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ANIP: 59.54
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 14.27, Med: 53.65, Max: 5654
Current: 59.54
14.27
5654
Forward PE Ratio 11.99
Forward P/E ranked higher than
90.91% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
ANIP: 11.99
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 59.54
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ANIP: 59.54
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 14.27, Med: 55.22, Max: 5654
Current: 59.54
14.27
5654
PB Ratio 4.05
PB Ratio ranked higher than
54.47% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ANIP: 4.05
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.82, Med: 4.03, Max: 29.66
Current: 4.05
0.82
29.66
PS Ratio 3.89
PS Ratio ranked higher than
78.93% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ANIP: 3.89
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.82, Med: 8.33, Max: 858.69
Current: 3.89
0.82
858.69
Price-to-Free-Cash-Flow 27.33
Price-to-Free-Cash-Flow ranked lower than
90.79% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ANIP: 27.33
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.62, Med: 27.91, Max: 288.62
Current: 27.33
8.62
288.62
Price-to-Operating-Cash-Flow 13.82
Price-to-Operating-Cash-Flow ranked higher than
88.57% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ANIP: 13.82
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.22, Med: 23.72, Max: 167.35
Current: 13.82
7.22
167.35
EV-to-EBIT 29.70
EV-to-EBIT ranked lower than
58.24% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ANIP: 29.7
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -33.7, Med: 9.25, Max: 516.6
Current: 29.7
-33.7
516.6
EV-to-EBITDA 13.06
EV-to-EBITDA ranked higher than
64.06% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ANIP: 13.06
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -43.4, Med: 10.45, Max: 169.6
Current: 13.06
-43.4
169.6
EV-to-Revenue 4.67
EV-to-Revenue ranked higher than
75.88% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ANIP: 4.67
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -2.9, Med: 7.3, Max: 978.2
Current: 4.67
-2.9
978.2
PEG Ratio 0.97
PEG Ratio ranked lower than
100.00% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
ANIP: 0.97
Ranked among companies with meaningful PEG Ratio only.
N/A
Current Ratio 0.92
Current Ratio ranked lower than
56.05% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ANIP: 0.92
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.92, Med: 5.17, Max: 30.07
Current: 0.92
0.92
30.07
Quick Ratio 0.67
Quick Ratio ranked lower than
61.82% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ANIP: 0.67
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.67, Med: 5.17, Max: 28.24
Current: 0.67
0.67
28.24
Days Inventory 211.84
Days Inventory ranked lower than
66.53% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ANIP: 211.84
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 55.94, Med: 148.04, Max: 300.6
Current: 211.84
55.94
300.6
Days Sales Outstanding 118.30
Days Sales Outstanding ranked lower than
79.49% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ANIP: 118.3
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 18.86, Med: 115.11, Max: 151.83
Current: 118.3
18.86
151.83
Days Payable 57.26
Days Payable ranked lower than
67.16% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ANIP: 57.26
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 16.76, Med: 69.4, Max: 23002.3
Current: 57.26
16.76
23002.3

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.80
3-Year Share Buyback Rate ranked higher than
90.90% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ANIP: -0.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -61.9, Med: -31.45, Max: -0.8
Current: -0.8
-61.9
-0.8

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.47
Price-to-Median-PS-Value ranked higher than
86.43% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ANIP: 0.47
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.13, Med: 1.71, Max: 155.34
Current: 0.47
0.13
155.34
Earnings Yield (Joel Greenblatt) % 3.37
Earnings Yield (Greenblatt) ranked higher than
86.03% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ANIP: 3.37
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8079.9, Med: 1.7, Max: 3460.4
Current: 3.37
-8079.9
3460.4

More Statistics

Revenue (TTM) (Mil) $ 207.98
EPS (TTM) $ 1.15
Beta 1.97
Volatility % 45.47
52-Week Range $ 36.92 - 74
Shares Outstanding (Mil) 12.05

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N